Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures

This technology includes a semi-automatic and affordable protein purification system that produces purified proteins with yields and purities comparable to an automatic protein purification system for less than 10% of its cost, which can be used for studying protein structure and function, as well as antibody purifications and drug screenings. Additionally, the new system is flexible and customizable for use with both custom-made and commercial pre-made resin columns with either gravity flow or low-pressure configurations.

Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents

This technology includes a compound for use as a selective agonist of the A1 adenosine receptor (AR) for therapeutic hypothermia and other conditions. We have examined various synthesized nucleosides in a model of mouse hypothermia, in conjunction with AR knockout mice, to characterize the biological profiles. In trying to identify novel highly selective A1AR agonists that have superior in vivo activities, we have adapted a means of rigidifying the ribose moiety of adenosine in the form of a bicyclic (N)-methanocarba ring.

MicroRNAs for Cell Line Utilization and Future Therapeutic Application

This technology includes microRNAs for use in cell lines for protein production and potentially future treatments of cancer or diseases related to metabolism. Mmu-miR-466h was identified as a major apoptotic regulator in suspension adapted Chinese Hamster Ovary cells. Mmu-miR-466h was found to have the pro-apoptotic activity by targeting some anti-apoptotic genes for degradation during the exposure of CHO-S cells to the nutrients depleted media.

Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics

This technology includes an alternative synthetic biotin-streptavidin replacement system for use in the development of clinical diagnostics. Peptide nucleic acids (PNA) when functionalized onto the surface of microspheres are capable of targeting short RNA targets from solutions. However, when the target nucleic acid becomes longer and complicated in structure, the PNA no longer efficiently binds due to steric hindrance from the microspheres and/or slow hybridization kinetics of larger nucleic acid targets.

Ionophores as Treatment for Sickle Cell Disease

This technology includes a method using ionophores to reduce sickling in patients with sickle cell disease. Sickle cell disease is caused by polymerization of a hemoglobin mutant, and the only approved treatment acts by replacing sickle hemoglobin with fetal hemoglobin, thereby increasing the delay time prior to polymerization. This drug is only partially successful because it does not induce fetal hemoglobin synthesis in all cells.

HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency

This technology includes an engineered HEK293 cell line expressing firefly luciferase by functionally knocking out the caspase 8 associated protein 2 (CASP8AP2) gene using CRIPSR/Cas9 genome editing for improved production efficiency. This engineered cell line possesses superior recombinant protein expression capabilities than the parental cell line from which it was created, while proliferating and metabolizing carbon at a comparable rate. Improved recombinant protein expression is mediated by growth arrest at the G0/G1 phase.

Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses

This technology includes compounds that are selective agonists of the A3 receptor for the treatment of various disorders such as cancer and autoinflammatory diseases. Structurally, these compounds extend the class of (N)-methanocarba derivatives that are selective agonists of the A3 receptor.

Composition and Methods for Modulation of Thyrotropin Releasing Hormone for the Treatment of Cancer-related Fatigue

This technology includes a series of small molecule TRHR agonists for the treatment of cancer-related fatigue. In particular, PTLS-04 and PTLS-11 have shown excellent TRHR agonist activities in mouse and human cells and have improved metabolic profile compared to TRI I and taltirelin. Additional work is being done to further optimize the series by designing and synthesizing additional compounds.